Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repairdoi:10.1007/s00392-024-02490-7To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing ...
Atrial fibrillation (AF) is a common arrhythmia associated with increased morbidity and mortality, particularly in patients with heart failure with reduced ejection fraction (HFrEF). Catheter ablation has emerged as an effective treatment option for AF and has been shown to have mortality benefits in...
Our results suggest that future efforts to improve HF care that are focused on longitudinal outpatient follow-up may represent the greatest opportunity for patient benefit. Potential Explanations for Observed Trends During the past 2 decades, there have been medical advances throughout the spec...
Randomized testing of rhythm control with drugs and cardioversion did not demonstrate mortality benefit over rate control5; however, subsequent analyses suggest that the benefit of sinus rhythm has been offset by the deleterious effects of antiarrhythmic drugs and inappropriate interruption of antico- ag...
Yet, we observed that obesity was not a significant risk factor for five-year mortality in patients with advanced HF and that excess body weight may, in fact, confer survival benefit to patients with HF. Despite the wide prevalence of both HF and obesity, few previous studies have addressed ...
The study was stopped earlier than planned due to the significant benefit achieved with metoprolol CR/XL on all-cause mortality. Treatment with metoprolol CR/XL was associated with a 34% decrease in all-cause mortality, 38% decrease in cardiovascular mortality, 41% decrease in sudden death, and...
Patients at low risk could be potentially discharged from the hospital early, whereas those at high risk could benefit from intensive or specialized care units. Previous work in heart failure risk determination focused primarily on risk adjustment in elderly Medicare populations.14-16 These prior ...
Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178鈥 87. CrossRef Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Early and sustained benefit on event-free survival and...
摘要: American Journal of Cardiology, The - Vol. 109 - N° 5 - p. 712-717 - Comparison of Benefit and Mortality of Implantable Cardioverter–Defibrillator Therapy in Patients Aged ≥75 Years Versus Those <75 Years - EM|consulte...
Acute renal failure is associated with high mortality and morbidity. Diuretic agents continue to be used in this setting despite a lack of evidence supporting their benefit.To determine whether the use of diuretics is associated with adverse or favorable outcomes in critically ill patients with acute...